It is one of the molecular mechanisms for the process of pulmonary fibrosis, in which interfering the expressing of TSSK4 or regulating the activity of AKT could be the potential therapeutic strategies to improve pathological process of IPF. The gene discussed is AKT1; the disease is idiopathic pulmonary fibrosis.